We showed that the dual SHP2 inhibitor PHPS1 [34] effectively sensitized human HER2iR breast cancer cells to lapatinib (Supplementary Fig. S5a–d), suggesting that aberrant SHP2 signaling may confer resistance to HER2 inhibitors in HER2+ BC cells. Here, ERBB2 is linked to breast cancer.